This company has been acquired
GRNA Stock Overview
GreenLight Biosciences Holdings operates as a pre-commercial stage biotechnology company in the United States of America.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
GreenLight Biosciences Holdings Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.30 |
| 52 Week High | US$5.90 |
| 52 Week Low | US$0.18 |
| Beta | 1.44 |
| 1 Month Change | 3.20% |
| 3 Month Change | -6.08% |
| 1 Year Change | -85.25% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.94% |
Recent News & Updates
Recent updates
GreenLight Biosciences cutting 25% of staff as part of realignment
Oct 12GreenLight Biosciences launches $109M in financing
Aug 12GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine
Aug 01GreenLight Biosciences: Synthesizing Cell-Free RNA
Apr 05Shareholder Returns
| GRNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.4% | -1.5% | -0.7% |
| 1Y | -85.2% | 0.1% | 22.3% |
Return vs Industry: GRNA underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: GRNA underperformed the US Market which returned 13% over the past year.
Price Volatility
| GRNA volatility | |
|---|---|
| GRNA Average Weekly Movement | 16.1% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GRNA's share price has been volatile over the past 3 months.
Volatility Over Time: GRNA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Andrey Zarur | greenlightbiosciences.com |
GreenLight Biosciences Holdings operates as a pre-commercial stage biotechnology company in the United States of America. It provides cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company’s plant and animal health pipeline includes Calantha for the Colorado potato beetle; Varroa mites, an RNA-based syrup that targets reproductive mites; Vegetable Caterpillar Complex, an dsRNA-based pesticide for the Diamond Back Moth; and Spider Mite Complex for the control of Tetranychus urticae.
GreenLight Biosciences Holdings Fundamentals Summary
| GRNA fundamental statistics | |
|---|---|
| Market cap | US$45.43m |
| Earnings (TTM) | -US$157.32m |
| Revenue (TTM) | US$10.34m |
4.4x
P/S Ratio-0.3x
P/E RatioIs GRNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRNA income statement (TTM) | |
|---|---|
| Revenue | US$10.34m |
| Cost of Revenue | US$129.70m |
| Gross Profit | -US$119.35m |
| Other Expenses | US$37.96m |
| Earnings | -US$157.32m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.04 |
| Gross Margin | -1,153.96% |
| Net Profit Margin | -1,521.00% |
| Debt/Equity Ratio | 111.6% |
How did GRNA perform over the long term?
See historical performance and comparison